Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of non-qualified stock options for 20,480 shares and 11,620 restricted stock units to two new non-executive officers. Approved by the compensation committee, these awards aim to attract talent under the Ultragenyx Employment Inducement Plan. The options have a ten-year term with an exercise price of $70.69 per share, equivalent to the closing price on April 29, 2022. The restricted stock units vest over four years, while the options vest gradually over the same period, contingent on ongoing employment.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:40 PM ET. Key executives, including Chief Medical Officer Camille Bedrosian and Chief Financial Officer Mardi Dier, will lead the presentation. Interested parties can access the live and archived webcast on the company's website for 90 days following the event. Ultragenyx is dedicated to developing innovative therapies for rare and ultra-rare genetic diseases, with a focus on addressing high unmet medical needs.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its upcoming conference call scheduled for May 5, 2022, at 5:00 PM ET to discuss financial results for Q1 2022. The call will provide updates on the company's performance and strategy in treating rare genetic diseases. Investors can participate via phone or access a live and recorded webcast on the company’s website. Ultragenyx is focused on developing novel therapies for serious rare and ultra-rare genetic disorders, emphasizing time-efficient drug development to meet patient needs.
Summary not available.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has appointed Amrit Ray, M.D., M.B.A., to its Board of Directors, specifically on the Research and Development Committee. Dr. Ray brings extensive experience as a physician researcher and executive, previously serving as Chief Patient Officer at Biohaven Pharmaceuticals and holding senior roles at Pfizer and Johnson & Johnson. His expertise is expected to enhance Ultragenyx's commitment to developing innovative treatments for rare diseases. The company focuses on delivering novel therapeutic products to address significant unmet medical needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the initiation of the global Orbit study, a pivotal Phase 2/3 trial for UX143 to treat Osteogenesis Imperfecta (OI) in patients aged 5 to 26. This study follows the promising results of the Phase 2b study, which showed significant improvements in bone density. The Orbit study aims to assess fracture risk reduction in younger populations, with plans for additional studies in other age groups. The collaboration with Mereo BioPharma continues to support the development of UX143 for OI.
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have its CEO, Emil D. Kakkis, participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 PM ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 90 days. Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, boasting a diverse portfolio aimed at addressing high unmet medical needs. The management team is dedicated to efficient drug development to deliver safe and effective therapies rapidly.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported total revenue of $351.4 million for 2021, with $192.6 million from Crysvita. The company anticipates Crysvita revenue between $250 million and $260 million for 2022. Dojolvi revenue guidance is $55 million to $65 million. The year-end cash balance stands at $1.0 billion. Despite revenue growth, Ultragenyx posted a net loss of $454 million, or $6.70 per share, reflecting increased operating expenses. The company is focused on expanding its clinical pipeline and commercializing Evkeeza in Europe.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on February 10, 2022, at 5:00 PM ET to discuss its financial results for Q4 and the full year ended December 31, 2021. The call will detail the company’s performance and corporate updates. A live and replayed webcast will be accessible on the company’s website, ensuring transparency regarding its operations in developing therapies for rare diseases. Ultragenyx focuses on addressing high unmet medical needs with its innovative therapies.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of non-qualified stock options for 16,050 shares and 5,350 restricted stock units to two newly hired non-executive officers. These awards, approved by the board's compensation committee, were made under the Ultragenyx Employment Inducement Plan as an inducement to the new hires. The options vest over four years with a starting exercise price of $72.04, equal to the closing stock price on February 1, 2022. The company focuses on developing therapies for rare diseases, aiming for rapid and efficient drug development.